1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. OptiNose, Inc.
  6. Summary
    OPTN   US68404V1008

OPTINOSE, INC.

(OPTN)
  Report
Delayed Nasdaq  -  04:00 2022-08-09 pm EDT
3.500 USD   -2.78%
08/08Optinose Announces Reporting Date for Second Quarter 2022 Financial Results
AQ
07/13OPTINOSE : Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program - Form 8-K
PU
07/13OPTINOSE, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/03/2022 08/04/2022 08/05/2022 08/08/2022 08/09/2022 Date
3.67(c) 3.68(c) 3.68(c) 3.6(c) 3.5(c) Last
168 789 86 790 45 667 139 312 84 579 Volume
+1.38% +0.27% 0.00% -2.17% -2.78% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 90,8 M - -
Net income 2022 -69,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,17x
Yield 2022 -
Sales 2023 129 M - -
Net income 2023 -27,1 M - -
Net Debt 2023 - - -
P/E ratio 2023 -9,93x
Yield 2023 -
Capitalization 289 M 289 M -
Capi. / Sales 2022 3,19x
Capi. / Sales 2023 2,24x
Nbr of Employees 191
Free-Float 73,6%
More Financials
Company
OptiNose, Inc. is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), is a therapeutic utilizing the Company's Exhalation Delivery System (EDS), which delivers a topically acting corticosteroid... 
Sector
Pharmaceuticals
Calendar
08/16Earnings Release
More about the company
Ratings of OptiNose, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about OPTINOSE, INC.
08/08Optinose Announces Reporting Date for Second Quarter 2022 Financial Results
AQ
07/13OPTINOSE : Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Pati..
PU
07/13OPTINOSE, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/13Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Pat..
AQ
07/13Optinose Announces XHANCE Significantly Reduced Incidence of Exacerbations for Patients..
CI
07/08OptiNose Says Additional Analyses From Phase 3 Trials for Treatment of Chronic Sinusiti..
MT
07/08OPTINOSE : Announces Additional Positive Results from ReOpen2 and Initial Results from Poo..
PU
07/08OPTINOSE, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/08Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Po..
AQ
07/08Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Po..
CI
07/01OPTINOSE, INC. : Termination of a Material Definitive Agreement, Financial Statements and ..
AQ
06/24OPTINOSE, INC.(NASDAQGS : OPTN) added to Russell 3000E Value Index
CI
06/24OPTINOSE, INC.(NASDAQGS : OPTN) added to Russell Microcap Value Index
CI
06/17INSIDER SELL : Optinose
MT
06/13OPTINOSE : ReOpen2 Topline Results
PU
More news
News in other languages on OPTINOSE, INC.
07/13Optinose annonce que XHANCE a réduit de manière significative l'incidence des exacerbat..
07/08OptiNose déclare que des analyses supplémentaires des essais de phase 3 pour le traitem..
07/08Optinose annonce des résultats positifs supplémentaires de ReOpen2 et les premiers résu..
06/13OptiNose présente les résultats positifs d'un essai clinique pour le traitement de la s..
06/13Optinose annonce les premiers résultats positifs de Reopen2, son deuxième essai cliniqu..
More news
Analyst Recommendations on OPTINOSE, INC.
More recommendations
Chart OPTINOSE, INC.
Duration : Period :
OptiNose, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPTINOSE, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 3,50 $
Average target price 7,50 $
Spread / Average Target 114%
EPS Revisions
Managers and Directors
Peter Kaighn Miller Chief Executive Officer & Director
Ramy A. Mahmoud President & Chief Operating Officer
Michele Janis Chief Financial Officer & Vice President-Finance
Joseph C. Scodari Independent Chairman
John C. Messina SVP-Clinical Development & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
OPTINOSE, INC.116.05%289
JOHNSON & JOHNSON-0.52%447 434
ELI LILLY AND COMPANY9.70%287 922
PFIZER, INC.-16.05%279 310
ROCHE HOLDING AG-16.02%275 991
ABBVIE INC.3.58%247 976